Join Growin Stock Community!

Acrivon therapeutics, inc. common stockACRV.US Overview

US StockHealthcare
(No presentation for ACRV)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ACRV AI Insights

ACRV Overall Performance

ACRV AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ACRV Recent Performance

-1.32%

Acrivon therapeutics, inc. common stock

0.05%

Avg of Sector

-0.31%

S&P500

ACRV PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ACRV Key Information

ACRV Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ACRV Profile

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Price of ACRV

ACRV FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ACRV Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.59
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.45
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.59
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.45
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%

  • When is ACRV's latest earnings report released?

    The most recent financial report for Acrivon therapeutics, inc. common stock (ACRV) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ACRV's short-term business performance and financial health. For the latest updates on ACRV's earnings releases, visit this page regularly.

  • How much debt does ACRV have?

    As of the end of the reporting period, Acrivon therapeutics, inc. common stock (ACRV) had total debt of 2.99M, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ACRV have?

    At the end of the period, Acrivon therapeutics, inc. common stock (ACRV) held Total Cash and Cash Equivalents of 35.61M, accounting for 0.25 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ACRV's EPS continuing to grow?

    According to the past four quarterly reports, Acrivon therapeutics, inc. common stock (ACRV)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.47. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ACRV?

    Acrivon therapeutics, inc. common stock (ACRV)'s Free Cash Flow (FCF) for the period is -13.18M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 28.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ACRV?

    The latest valuation data shows Acrivon therapeutics, inc. common stock (ACRV) has a Price-To-Earnings (PE) ratio of -0.8 and a Price/Earnings-To-Growth (PEG) ratio of 0.07. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.